• Explore /
  • Poster
  • / Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.

Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.

Abstract Poster

Authors

null

Doudou Li

Fudan University Shanghai Cancer Center, Shanghai, China

Doudou Li , Zhonghua Tao , Biyun Wang , Leiping Wang , Jun Cao , Xichun Hu , Jian Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT03254654

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1075)

DOI

10.1200/JCO.2021.39.15_suppl.1075

Abstract #

1075

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma.

Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma.

First Author: Lingbin Meng

First Author: Shun Tezuka

First Author: Ting Han

First Author: Feng Wang